ATMPs Publications and Research Funding Opportunities

Research – from early-stage drug discovery through to manufacturing and clinical research – is the life-blood of the rapidly-evolving advanced therapeutics sector. Over recent years Ireland’s research-performing institutes have developed a bedrock of research talent and expertise and are building a portfolio of innovative research projects. In parallel, Ireland has developed a wide range of state research funding sources and supports.

This section of the Advanced Therapeutics Ireland portal pulls together the latest research funding opportunities and highlights the latest ATMP research publications.

 

Below you will find a selection of Horizon Europe funding calls relevant to advanced therapies. For a complete overview of all calls, please refer to the Horizon Europe Work Programme 2025-2026 document.

Funding Opportunities

Funding Call Targeted/Untargeted Funder Website

  • The Strategic Partnership Programme is a flexible mechanism for academic researchers to build strategic collaborations with key stakeholders such as industry, other funding agencies, charities, philanthropic organisations, higher education institutes (HEIs), or a combination of any of these. The scheme aims to support stand-alone research initiatives of scale with strong potential for delivering economic and societal impact to Ireland, in partnership with key stakeholders.

    Funder:
    Research Ireland

    Call Status:
    Open – Rolling Call

    Untargeted
    Source

  • The US-Ireland Research and Development Partnership is a unique initiative involving funding agencies across three jurisdictions: United States of America, Republic of Ireland & Northern Ireland. The overall goal of the Partnership is to increase the level of collaborative R&D amongst researchers and industry across the three jurisdictions. This collaboration aims to generate valuable discoveries and innovations which are transferable to the marketplace, or will lead to enhancements in health, disease prevention or healthcare.

    Funder:
    Research Ireland

    Call Status:
    Open – Rolling Call

    Targeted
    Source

  • EPSRC and Research Ireland have an established agreement to welcome, encourage and support research applications that cut across national boundaries involving collaborative teams led by researchers from the UK and Ireland. This Partnership supports joint research and technology development in all areas of EPSRC’s remit which covers chemistry, engineering, information and communications technologies, materials, mathematical sciences and physics.

    Funder:
    Research Ireland

    Call Status:
    Open – Rolling Call

    Targeted
    Source

  • The Research Ireland Frontiers for the Future Programme provides opportunities for independent investigators to conduct highly innovative, collaborative research with the potential to deliver impact, whilst also providing opportunities for high-risk, high-reward research projects.

    Funder:
    Research Ireland

    Call Status:
    2024 Call: Projects stream is CLOSED
    2024 Call: Awards stream is OPEN Rolling Call

    Untargeted
    Source

  • The Disruptive Technologies Innovation Fund (DTIF) is a €500 million challenge-based fund established under Project Ireland 2040. It is one of four funds set up under the National Development Plan (NDP) 2018-2027. It is managed by the Department of Enterprise, Trade and Employment and administered by Enterprise Ireland.

    To date, over €371 million in funding has been awarded to 104 projects.

    DTIF Call 7 launched on 7 May 2024 and is accepting applications until 30 April 2025.

    DTIF is suitable for combinations of SMEs, MNCs and RPOs who are engaging in collaborative ‘industrial research’ and/or ‘experimental development’ towards a common objective.

    You should apply to DTIF if your project will potentially:

    • alter markets
    • alter the way businesses operate
    • involve the creation of new products or
      contribute to the emergence of new business models

    Projects are assessed based on four criteria:

    • strength of the disruptive technology dimension
    • excellence of the overall proposal and approach
    • economic impact and sustainability
    • quality and efficiency of the collaboration

     

    Funder:

    Enterprise Ireland

    Call Status:
    Call OPEN (until 30 April 2025)

    Untargeted
    Source

  • This funding programme encourages Irish-based companies to work with Irish researchers to undertake research which supports the development of new and improved products, processes, services and generate new knowledge and know-how.

    Funder:
    Enterprise Ireland

    Call Status:
    Call OPEN (multiple cut-offs per year)

    Untargeted
    Source

  • Destination 5 – Developing and using new tools, technologies and digital solutions for a healthy society

    Tissue-specific functional 3D bio-printing of living cells has made significant progress as a new approach for transplantation applications in regenerative medicine. There are currently several types of bio-printing technologies under development for the repair of different targeted tissues or organs. To fully unleash the potential of bio-printed cell constructs for regenerative medicine several bottlenecks still need to be overcome. Various studies in pre-clinical models have shown that bio-printed cell constructs or tissues hold great
    promise for regenerative medicine, by allowing autologous tissue grafts being printed thus avoiding adverse graft-host reactions. However, translation of such approaches into clinical settings (i.e. humans) and their application to internal organs still needs to be investigated and demonstrated.

    Funder:
     Horizon Europe

    Call Opening : 3 June 2027

    Call Deadline : 22 September 2027

    Targeted
    Source

  • Destination 5 – Developing and using new tools, technologies and digital solutions for a healthy society

    Research and innovation is essential for economic growth and boosting the competitiveness of the EU’s life sciences sector. Through the Horizon 2020 and Horizon Europe Framework Programmes, the EU has supported projects that significantly impact our health by fostering scientific discoveries and developing new solutions. Transformational health innovations, such as
    mRNA vaccines, highlight the importance of collaboration among businesses, research institutions, and healthcare providers.

    Funder:
     Horizon Europe

    Call Opening : 10 February 2026

    Call Deadline : 16 April 2026

    Targeted
    Source

  • Destination 5 – Developing and using new tools, technologies and digital solutions for a healthy society

    This topic aims to support the ongoing paradigm shift in biomedical research and
    safety assessment of chemical compounds by fully integrating NAMs across the entire
    research and regulatory spectrum, from basic discovery phase to clinical application, and
    regulatory testing of medicinal products and medical devices, and/or industrial and
    environmental chemicals.

    Funder:
     Horizon Europe

    Call Opening : 10 February 2026

    Call Deadline : 16 April 2026

    Targeted
    Source

  • Destination 6 – Maintaining an innovative, sustainable, and competitive EU health industry

    The development, uptake and impact of health technologies typically results from a long product development process that is based on a ‘life cycle approach’ which typically involves several iterations of defined stages, i.e. from development, assessment to post-market surveillance and post-market clinical follow-up.
    While health technologies are governed by comprehensive legal frameworks aiming to ensure that health technologies are safe and effective, the regulatory science underlying these legal frameworks needs to be updated.
    Funder:
     Horizon Europe

    Call Opening : 10 February 2026

    Call Deadline : 16 April 2026

    Targeted
    Source

  • Destination 3 – Tracking diseases and reducing disease burden

    Infectious diseases remain a major threat to health and health security in the EU and globally. Viral disease emergence is already being accelerated by climate change, and thus a proactive approach to the development of vaccine-based antiviral prophylactics and therapeutics in preparedness for future infectious disease outbreaks is needed. The availability of vaccines that can be adjusted to variants would provide a critical preparedness measure against future health threats, due to infectious disease epidemics or pandemics.
    Funder:
     Horizon Europe

    Call Opening : 10 February 2026

    Call Deadline : 16 April 2026

    Targeted
    Source

  • The fundamental focus of the ERC through its main frontier research grants (e.g. Starter, Consolidator and Advanced Grants) is to provide attractive, long-term funding to support excellent investigators and their research teams to pursue ground-breaking high-gain/high-risk research. Research funded by the ERC is expected to lead to advances at the frontiers of knowledge and to set a clear and inspirational target for frontier research across Europe.

    Funder:
     Horizon Europe

    Call Status:
    Starting Grant 2022 call closed (13 Jan 2022); next call deadline 25 October 2022 (anticipated) Consolidator Grant 2022 call closed (17 March 2022); next call deadline 2 February 2023 (anticipated) Advanced Grant 2022 call closed (28 April 2022); next call deadline 23 May 2023 (anticipated)

    Untargeted
    Source

Publications

Publication Date Added Website

  • Increased-functional-potency-of-multi-edited-CAR-T

    Avectas, Cherrywood Business Park - Dublin, Ireland; University College London, Cancer Institute - London, UK
    Date:
    Source

  • Why Ireland for Cell and Gene Therapy Development and Manufacturing

    IDA Ireland
    Date:
    Source

  • The Case for Cell and Gene Therapy Manufacturing in Ireland

    The CGT Forum members
    Date:
    Source

  • AAV-mediated gene therapy improving mitochondrial function provides benefit in age-related macular degeneration models

    Sophia Millington-Ward, Naomi Chadderton, Laura K. Finnegan, Iris J.M. Post, Matthew Carrigan, Tom Gardiner, Elisa Peixoto,Daniel Maloney, Marian M. Humphries, Alan Stitt, Thierry Léveillard, Pete Humphries, Paul F. Kenna, Arpad Palfi, G. Jane Farrar
    Date:
    Source

  • CGT Forum Working Group 7 Report 2022

    Drafted by Cormac Kennedy; Reviewed by Working Group 7
    Date:
    Source

  • Proteomic Landscape of Adeno-Associated Virus (AAV)-Producing HEK293 Cells

    Lisa Strasser, Stefano Boi, Felipe Guapo, Nicholas Donohue, Niall Barron, Alana Rainbow-Fletcher, Jonathan Bones
    Date:
    Source

  • The Regulatory Landscape for ATMPs in the EU and US: a Comparison

    Shada Warreth, Elaline Harris
    Date:
    Source

Get the Latest News & Events

Our community is growing rapidly, and we want you to be a part of it. Subscribe to our newsletter today by entering your email and signing up!

This field is for validation purposes and should be left unchanged.